Sangamo Biosciences (SGMO) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Biosciences (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $3.94 million versus the consensus estimate of $5.49 million.
GUIDANCE:
Sangamo Biosciences sees FY2016 revenue of $20-25 million, versus the consensus of $22.76 million.
For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SolarMax Technology (SMXT) Misses Q2 EPS by 98c
- Chilean Cobalt expands NeoRe rare earth project area to 67,400 hectares
- Truist Names Top Infrastructure Services Stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
